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FK 506 Prevents Spontaneous Diabetes in the BS Rat 
N. Murase, I. Lieberman, M. Nalesnik, D. Mintz, S. Todo, AL Drash, and T.E. Starzl 
RAPIDLY fatal insulin-<iependent diabetes of an au-
toimmune etiology appears between the ages of 40 
and 140 days in 40% to 75% of BB Wistar rats. ,·7 A typical 
insulitis lesion precedes the diabetic state followed by a 
selective destruction of the beta cells. leaving alpha and 
delta cells intact: ' -4 without insulin treatment. the animals 
die within a few days. The process is genetica1ly pro-
grammed and islet directed.7 but there may be other 
simultaneous autoimmune disorders such as lymphocytic 
thyroiditis.s Cyclosporine (CyA) can mitigate or prevent 
BB rat diabetes. H 
FK 506. a potent new immunosuppressive agent. can 
prevent or reverse allograft rejection after clinical organ 
transplantatlon.9• 11 by suppressing T-cell activation in the 
same genera! way as CyA. 12•13 Both drugs inhibit the 
transcription of messenger RNAs (mRNAs) for early 
phase Iymphokines. such as IL-2. IL-). and interferon-
gamma. but FK 506 is more potent. 14 FK 506 can prevent 
an autoimmune disease in MRL-lpr/lpr mice. which resem-
bles human systemic lupus erythematosus . ., Patients with 
hemolytic uremic syndrome. 16 glomerulonephritis with the 
nephrotic syndrome. 17 psoriasis. (unpublished observa-
tions). and pyoderma gangrenosum (unpublished observa-
tions) have also been put into remission with FK 506. 
In this study. the ability of FK 506 to prevent the 
spontaneous diabetic syndrome in BB rats was demon-
strated with two different doses. Many of the animals 
continued to be free of diabetes after discontinuance of the 
drug. 
MATERIAL AND METHODS 
Animals 
The BB rat colony of the University of Pittsburgh (Pittsburgh. PAl 
was started from initial breeding stocks obtamed from the Uni-
versity of Massachusetts (Boston. MA) in August 1986. The rats 
have been inbred over 10 generations and develop spontaneous 
diabetes at a 60% to 90% incidence in both sexes between ao and 
190 days of age. with the peak incidence between 110 and 100 days. 
All animals received tap water and regular rat chow I Purina Rat 
Chow 5001) ad hbitum under controlled lighting conditions. 
FK 506 
FK 506 was a gUt by Fujisawa Pharmaceutical Co .. Ltd (Osaka. 
Japan,. The oral fonn of FK 506. dispersed with hydroxvpropyl 
methylcellulose. was diluted in tap waler by sonication. and was 
.ldministered daily by gastnc gavage. 
Expenmental Design 
:\ total of 59 B8 rats was obtamed from seven consecuuve litters. 
Animals from each litter were randomly divided into three sex-
matched groups. Animals 1ft an untreated group received tap 
water (group I. n - 20). In the treatment groups. mtragastnc FK 
506 doses were given at 1.0 mglkgld (group 2. n = 19) and 2.0 
mg/Q'd (group 3. n = 20). Treatment was started at 30 days of age 
and continued for 90 days. Body weight and glycosuria (Testape. 
Eli Lilly. Indianapolis. IN) were measured three times a week. 
Blood glucose levels were measured by the glucose oxidase 
method as soon as glycosuria was seen and in all nonglycosuric 
animals every 14 days. Diabetes was diagnosed if the nonfasted 
glucose level exceeded 200 mgldL for 3 consecutive days. At the 
age of 120 days. following 90 days of treatment. six BB rats from 
each of the FK 506 treatment groups (groups 2 and 3). were 
randomly selected and killed for special studies. All other animals 
were followed until at least ISO days of age. 30 days or more after 
the discontinuance of FK 506. 
Assays 
Glucost Toltranct Ttst. At the age of 120 days on the last day 
of the treatment penod. blood samples were collected from the tail 
vein before and S. 10. 15. 30. 60. and 90 minutes after the 
intraperitoneal injection of 2 g/kg glucose (50% dextrose •• Tests 
were perfonned in the morning without anesthesia. 12 hours after 
food withdrawal. 
Insulin Extraction. After completing the glucose tolerance tests. 
the animals were killed and pancreatic tail tissue was diced in 
small pieces into the cold acid ethanol (absolute ethanol 75.2%. 
hydrochloric acid 1.4%. distilled water 23.4%) and sonacated 
vigorously for 10 minutes at .·C. After centrifugation at 500 rpm 
for 10 minutes. the supernatant fractions were frozen for subse-
quent assays of insulin by radioimmunoassay. 
Hutopatholof(Y. Tissues were routinely fixed in fonnalm. proc-
t:ssed. and paraffin-embedded. Hematoxylin and eosin sections 
from the pancreatic head. body. and tail were examined by a 
pathologist without access to the experimental group code. Semi-
quanutative evaluation of islet-cell inftammauon was graded on a 
scale of 0 to. as follows: O. no m"ammatlon: I. single hyperchro-
matic nuclei within or adjacent to islets lin cases of doubt as to 
whether these did or did not represent Infiammatory cells. a grade 
of I was assigned': 2. mononuclear cell clusters occupying an area 
less than 25% of the islet: 3. infiammatory mfiltrates occupymg 
25% to 50% of total islet area: •• infiltrates mvolving greater than 
50% of total islet area. 
In addition to these lesions. foci of periductal mononuclear 
inftammation were also quantified. but not graded. 
Guinea pig anu-human msulin (tiiogenex Labs. San Ramon. 
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Fig 1. Onset and Incidence of diabetes under treatment with 1.0 
mg/kgld oral FK 506, (n = 19); 2.0 mglkgld FK 506, (n = 20): or 
water. (n = 20) from 30 to 120 days of age. 
CAl and rabbit anti·human glucagon (Amersham Internauonal. 
Amersham. UK) have sufficient cross·reactivity with the respec· 
tive rat hormones to allow immunohistocherrucal detecuon. Lo-
calization of these antibodies onto fixed. paraffin-embedded tis· 
sues was visualized using the avidin·biotin procedure (Vector 
Labs Inc. Burlingame. Calli). Color was developed with 3·amino-
9-ethyl carbazole (Biomeda Corporation. Foster City. CAl. The 
entire procedure was performed on a computer-driven robot 
(Code·On •• Fisher Scientific Inc. Pittsburgh, PAl which allowed 
the placement of parallel control slides. 
RESULTS 
Incidence of Diabetes 
In untreated group 1. 15 of 20 (75%) of the animals 
developed diabetes between the age of 70 and 103 days 
(Fig I). None of the animals treated with daily doses of 2.0 
mg/kg FK 506 (group 3) developed glycosuria during 
treatment or for the 30 days following its discontmuance. 
With a dally dose of 1.0 mgtkgid (group 2), three animals 
became diabetic (15.7%) during therapy when they were 
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115. 117. and 120 days old. and two others developed 
diabetes after discontinuance of the drug when they were 
132 and 147 days old. 
Several animals in each group were killed for tissue at 
120 and between 150 and 185 days. The 10 remaining rats 
in the high FK 5Q6..dose series <group 3) remained nondi· 
abetic until 5 pregnant females became diabetic after 170 to 
190 days. The other five were still nondiabetic 90 to 120 
days after stopping FK 506. A long·tenn nondiabetic state 
was also frequently achieved in the low-dose group 2 FK 
506 series. 
Body Weight 
At the beginning of FK S06 treatment. mean body weights 
were nearly identical in the three groups. Body weight gain 
was slightly inhibited by FK 506 treatment both in the 
more rapidly growing males and in the females. but the 
differences were not statistically significant at most time 
points (Fig 2). 
Blood Glucose and Intrapentoneal Glucose Tolerance Test 
Nonfasting blood glucose levels during the 90 days of 
treatment in those animals that remained nondiabetic are 
summarized in Fig 3. The values were not different in the 
three groups, and were not significantly different than in 
nonnal Wistar Furth (non-BB) rats (data not shown). 
Intraperitoneal GTIs were perfonned in three nondia· 
betic animals of group 2 and 6 animals of group 3 at 120 
days. The curves were similar to those of nonnal Wistar 
Furth rats (Fig 4). 
Blood Chemistry and Pancreatic Insulin Content 
These were determined at the end of the FK 506 treatment 
in six nondiabetic survivors killed in group 2 and five killed 
in group 3 (the blood specimen from the sixth animal in this 
group was lostl. There was no increase of blood urea 
mal • 
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Fig 2. Effect of FK 506 treat· 
ment on body weight In males 
and females comparea WIth their 
male and female water-treatea 
Siblings. There were only five wa-
ter-treatea animals left at 120 
days. 
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Fig 3. Blood glucose levels at 30 to 120 days of age in nondia· 
betic survivors during FK 506 treatment (1.0 mQlkg. n = 16; 2.0 
mglkg. n = 20) compared with water treatment (n = 5). 
nitrogen. creatinine. glutamine-oxaloacetic transaminase 
(GOT). glutamic-pyruvic transaminase (GPT). or total 
bilirubin compared with six normal Wistar Furth (non-BB) 
rats (Table I). 
The pancreatic insulin content in these groups 2 and 3 
animals was not significantly different than in the normal 
Wistar Furth rats (Table 2). 
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Fig 4. Blood glucose levels during intrapentoneal glucose toler-
aoca test in BB rats treated with oral FK 506 (1.0 mQlkg and 2.0 
mQlkg) compared With nOnTIal Wistar Furth (non-BB) rats. Glucose 
(2 g/kg) was administered at 0 minutes. 
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Histology 
Pancreatic sections were examined from a total of 20 
animals (group I. (n = 5); group 2. (n = 6); group 3, (n = 
5); and normal Wistar-Furth controls. (n = 4). A total of 
1.473 islets were identified and graded as to degree of 
insulitis (Table 2). Each group was subdivided into animals 
that showed evidence of diabetes at death (group I A. 2A. 
etc) and those that did not (group lB. 2B. etc). Lesions of 
grade 2. 3. and 4. as well as foci of periductal inflammation. 
were found almost exclusively in animals that were dia-
betic. These lesions were markedly reduced in BB rats 
treated with low-dose FK 506 (group 2) and almost com-
pletely prevented with high-dose FK 506 treatment (group 
3). 
In a separate analysis. immunocytochemical studies 
were performed on tissue sections from 20 animals (group 
I. (n = 6); group 2. (n = 7); group 3. (n = 3); and the 
normal Wistar-Furth controls. (n = 4). The results of these 
studies are listed in Table 3. In normal Wistar-Furth 
animals. insulin-containing cells were clearly demarcated 
and generally inhabited the centers of the islets. Glucagon-
containing cells formed a distinct peripheral rim around the 
islet. With the development of diabetes in control animals. 
and in two animals of group 2 who developed diabetes in 
spite of low-dose FK 506 therapy. insulin-containing cells 
disappeared completely or became faintly stained. the islet 
size was reduced. and the cells stained only with antiglu-
cagon antibodies <Table 3). In contrast. normal-appearing 
distributions of insulin and glucagon-containing cells were 
observed in the five nondiabetic animals treated with 
low-dose FK 506 (group 2) and three of three high-dose FK 
506 (group 3) animals (Table 3). 
DISCUSSION 
There is much reason to believe that these studies in an 
autoimmune animal model have direct clinical relevance. 
Type I human diabetes is associated with specific HLA 
haplotypes DR3 and DR4 and an environmental triggering 
event is postulated to precipitate active autoimmunity and 
selective beta-cell destruction in genetically susceptible 
persons. 18 The same immunosuppressive treatment that 
can control the autoimmune process in BB rats should be 
effective in humans. In BB rats. prevention of diabetes was 
possible when treatment with Cy A was started before the 
onset of beta-cell destruction. H>.1'l.20 Subsequent clinical 
trials with CyA induced clinical remissions of type 1 
diabetes. providing therapy was started soon after the 
Table 1. Blood Chemistry and Pancreatic Insulin Content It 120 DaYlof Age 
Tolal Insullll 
BUN Creabnne GOT GPT BiRrua" Content 
Group (mgtdL) (mgldL) (UIl) (UIl) (mgtdL) (Ulg panaeaS) 
Group 2 6 24.0:: 6.9 0.8:: 0.2 130.3:: 93.0 33.8:: 9.3 0.7:: 0.2 5.4:: 3.5 
Group 3 5 29.8:: 5.4 1.0:: 0.4 134.6:: 69.1 35.0:: 9.4 0.6:: 0.4 2.7:: 2.4 
Wistar Furth 6 23.2:: 4.2 0.8:: 0.1 123.2:: 19.2 36.3:!: 2.9 0.4:: 0.2 3.2:: 0.6 
'Values are mean :!: SO. 
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Table 2. Frequency of PancredC LHIons In Treated and Umr.ted SS Am and In Normal WlNr Furth Am 
Total 
n Isleta 0(%) 
Group 1 Diabetic 4 144 
Nondiabetic 1 81 
Total 5 22S 
Group 2 Diabetic 1 66 
Nondiabetic 5 418 
Total 6 4&4 
Group 3 Diabetic 0 
Nondiabetic 5 334 
Total 5 334 
WIstar Furth Diabetic 0 
Nondiabetic 4 430 
ToWi 4 430 
'POI: penductal inllllll1matlOn (expntSMCI as pen:en1Ig8 ot IOtalllteta). 
diagnosis was made.21 -23 These trials could not reach their 
full potential because of nephrotoxicity caused by the 
drug. Recurrence of diabetes usually was observed 
promptly when Cy A was stopped or more slowly if the 
doses were too low. 
The therapeutic index of FK 506 in humans may be 
better-II and allow the promise of these earlier trials to be 
fulfilled. Administration of 2.0 mglkgld of FK 506 com-
Tible 3. Immunocytoc:hemlCllI Analyala ot Insulin and GluCll-
gon-Contlllning Cens In TfMted and Untre-.d SS Am and In 
WlNr Furth Alta Pine,.... 
Ar*nal 
Group No. Insulin Glucagon Outcome 
Group 1 (No 1 + Diabetic 
treatment) 2 + Diabetic 
3 + Diabetic 
4 + + NondiabetIC 
5 + NO Subcliabetic 
6 + DiabetIC 
Group 2 (FK 1 + + Nondiabetic 
5061.0 mg) 2 + NO Nondiabetic 
3 + NO Nondiabetic 
4 + + NondiabetIC 
5 +' +' Diabetic 
6 _a + DiabetIC 
7 + + NondIaDetlC 
Grauo 3 (FK 1 + + NondlaDetlC 
506 2.0 mg) 2 + NondIaDetIC 
3 + + NondiabetIC 
Wi star Funh 1 NondiabetIC 
2 + + NondiabetIC 
3 + NondiabetIC 
4 + + NondiabetIC 
'SuIIcIIaaeDc: nonnaIlIIOacI 91_. aDnOrmal 9I_1OIenI1IC8 leSt. 
°1'40: nor ClOne. 
'ReducacllII'-'Iy 01 ltatnnq. 
"Two "'- ooarwe. _ nega_. 
28 
52 
37 
3 
74 
64 
74 
74 
85 
85 
GI1Ide 
1(%) 2(%) 3(%) 4(%) POI 
33 27 6 6 56 
38 10 0 0 14 
35 21 4 4 40 
15 21 36 24 76 
25 1 0 4 
23 4 6 3 14 
25 0 0 0 2 
25 0 0 0 2 
15 0 0 0 0 
15 0 0 0 0 
pletely prevented the development of spontaneous diabe-
tes in BB rats. and greatly reduced the characteristic 
histopathologic changes in the pancreas. With immunoas-
say, insulin was found in nonnal quantities in the protected 
pancreases (Table I). and these findings were in confor-
mity with immunocytochemical studies (Table 3). Blood 
glucose levels of FK 506-treated animals remained in the 
nonnal range. Glucose intolerance. which has been de-
scribed in BB rats under CyA treatment.24 was not ob-
served with the doses of FK 506 used in this study. The 
therapeutic effect of a higher FK 506 dose far outlasted the 
time of active treatment. With a lower dose of FK 506 (1.0 
mg!kg). the prevention of pancreatic injury was less com-
plete but the posuherapy relapse rate of animals spared 
from diabetes was low. There was no mortality in this 
study except for that caused by diabetes. and toxic effects 
of FK 506 were not noted except for a slightly decreased 
rate of weight gam. Liver and renal function were unal-
tered. 
SUMMARY 
The BB rat is the experimental analogue of human juvenile 
diabetes mellitus. From 30 through 120 days after birth. 59 
BB rats were treated with water (n = 20). or FK 506 in 
daily intragastric doses of I mg/kg (n = 19) or 2 mg/kg (n = 
20). Diabetes developed in 75%. 15%. and 0% of the three 
groups. Animals protected from diabetes by FK 506. and 
killed in the nondiabetic state at 120 days had normal 
intrapentoneal glucose tolerance tests. virtual absence 
histopathologically of autoimmune insulitis. normal pan-
aeatic insulin content. and immunocytochemical confir-
mation of islet insulin and glucagon content. Forty five to 
75 days after stopping FK 506. about ¥4 of the ammals who 
were diabetes free at 120 days have remained so. These 
results provide support for a clinical trial of FK 506 for 
recent onset diabetes. 
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